Drugs giant GlaxoSmithKline saw a modest increase in group revenue in the first quarter of 2012 as growth in the US, Emerging Markets/Asia Pacific (EMAP) and Japan offset declines in Europe.
Total turnover amounted to £6,640m, up 2% at constant exchange rates (CER) or 1% on a reported basis.
Pharmaceuticals revenue rose 2% but was affect by continue pressure from austerity measures in Europe as well as slower growth in EMAP - this was driven particularly by "continued disruption in the Middle East, but also some broader sensitivity to a more challenging economic environment in a number of EMAP markets" the group said.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Vaccines turnover increased by 1% due to similar pressures as well as phasing of tenders and a demanding comparator. Meanwhile, Consumer Healthcare revenue rose 1% as growth was held back by the non-core over-the-counter (OTC) brands that the company is in the process of divesting.
The group achieved 6% CER growth in turnover in the US, its biggest market which accounts for £2,151m of sales. Its second-largest geography is Europe, where turnover declined by 5% (CER).
Total operating profit was flat at £2,037m, up 2% at CER. Pre-tax profit slumped to £1,879m, from £2,464m the year before after the prior-year figure was helped by profits on disposals.
The firm has confirmed a 6% increase in the first-quarter dividend to 17p and announced that total share buy-backs this year will be in the range of £2-2.5bn.
Shares were trading 1.85% lower at 1,430.5p at 12:15, just 15 minutes after the results were released.
BC
